Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 18/20 | 0.46 |
| ▸ | DDB1 | Q16531 | 3/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20359431 | 0.90 | CRBN (0.44) | CRBNDDB1HTT | |
| SCHEMBL8952307 | 0.88 | CRBN (0.43) | CRBNDDB1 | |
| SCHEMBL9028497 | 0.87 | CRBN (0.42) | CRBNDDB1 | |
| SCHEMBL677173 | 0.81 | CRBN (0.49) | CRBNDDB1HTT | |
| SCHEMBL20202002 | 0.78 | CRBN (0.43) | CRBNDDB1HTTGAA | |
| SCHEMBL6817697 | 0.76 | CRBN (0.50) | CRBNDDB1HTT | |
| SCHEMBL30897322 | 0.76 | GAA (0.51) | CRBNDDB1HTTGAA | |
| Acrylic Acid SCHEMBL31065415 | 0.74 | CRBN (0.43) | CRBNDDB1HTTGAA | |
| SCHEMBL2171319 | 0.74 | FAAH (0.40) | — | |
| Hydrochloric Acid SCHEMBL7450491 | 0.74 | GAA (0.50) | CRBNDDB1HTTGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11174271-B2 | 6-membered uracil isosteres | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2021-11-16 | — | — | US | disclosed |
| US-11124485-B2 | Deoxyuridine triphosphatase inhibitors containing cyclopropano linkage | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2021-09-21 | — | — | US | disclosed |
| US-20200283394-A1 | DEOXYURIDINE TRIPHOSPHATASE INHIBITORS CONTAINING CYCLOPROPANO LINKAGE | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2020-09-10 | — | — | US | disclosed |
| US-10544105-B2 | Deoxyuridine triphosphatase inhibitors containing cyclopropano linkage | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2020-01-28 | — | — | US | disclosed |
| US-20190270756-A1 | 6-MEMBERED URACIL ISOSTERES | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2019-09-05 | — | — | US | disclosed |
| US-20180201586-A1 | DEOXYURIDINE TRIPHOSPHATASE INHIBITORS CONTAINING CYCLOPROPANO LINKAGE | SAI LIFE SCIENCES LIMITED (IN) | 2018-07-19 | — | — | US | disclosed |
| WO-2018098204-A1 | 6-MEMBERED URACIL ISOSTERES | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2018-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10544105-B2 | Deoxyuridine triphosphatase inhibitors containing cyclopropano linkage | DPYD, DUT, TYMP | CRBN 3608/4885DDB1 108/4885HTT 4197/4885 |
| US-11174271-B2 | 6-membered uracil isosteres | UNG, DUT, DPYD | CRBN 3184/4885DDB1 80/4885HTT 3466/4885 |
| US-11124485-B2 | Deoxyuridine triphosphatase inhibitors containing cyclopropano linkage | DPYD, DUT, TYMP | CRBN 3608/4885DDB1 108/4885HTT 4197/4885 |
| US-20190270756-A1 | 6-MEMBERED URACIL ISOSTERES | UNG, DUT, DPYD | CRBN 3184/4885DDB1 80/4885HTT 3466/4885 |
| US-20180201586-A1 | DEOXYURIDINE TRIPHOSPHATASE INHIBITORS CONTAINING CYCLOPROPANO LINKAGE | DUT, DPYD, TYMP | CRBN 3374/4885DDB1 88/4885HTT 3607/4885 |
| US-20200283394-A1 | DEOXYURIDINE TRIPHOSPHATASE INHIBITORS CONTAINING CYCLOPROPANO LINKAGE | DPYD, DUT, TYMP | CRBN 3608/4885DDB1 108/4885HTT 4197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.